| Mehjabin Ismail Parkar, MD | |
|
6909 Brisbane Ct Ste 300, Sugar Land, TX 77479-4922 | |
| (281) 801-7855 | |
| (281) 801-7854 |
| Full Name | Mehjabin Ismail Parkar |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 6909 Brisbane Ct Ste 300, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508068438 | NPI | - | NPPES |
| BP1-0019446 | Other | INSTITUTIONAL PERMIT | |
| M8235 | Other | TX | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | M8235 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Altus Home Health, Llc | Sugar land, TX | Home health agency |
| Oakbend Medical Center | Richmond, TX | Hospital |
| Memorial Hermann Sugar Land Hospital | Sugar land, TX | Hospital |
| Entity Name | Texas Post Acute Specialists, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609314392 PECOS PAC ID: 9234407255 Enrollment ID: O20170615002605 |
News Archive
Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.
Children placed with a relative after being removed from their home for maltreatment have fewer behavioral and social skills problems than children in foster care, but may have a higher risk for substance use and pregnancy as teenagers, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
› Verified 4 days ago
| Entity Name | Claris Health Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356797070 PECOS PAC ID: 5496097396 Enrollment ID: O20190424002777 |
News Archive
Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.
Children placed with a relative after being removed from their home for maltreatment have fewer behavioral and social skills problems than children in foster care, but may have a higher risk for substance use and pregnancy as teenagers, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
› Verified 4 days ago
| Entity Name | Pai Participant 9 Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679135420 PECOS PAC ID: 7113254277 Enrollment ID: O20190812003650 |
News Archive
Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.
Children placed with a relative after being removed from their home for maltreatment have fewer behavioral and social skills problems than children in foster care, but may have a higher risk for substance use and pregnancy as teenagers, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
› Verified 4 days ago
| Entity Name | Oz Healthcare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083231245 PECOS PAC ID: 1254756026 Enrollment ID: O20200811000890 |
News Archive
Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.
Children placed with a relative after being removed from their home for maltreatment have fewer behavioral and social skills problems than children in foster care, but may have a higher risk for substance use and pregnancy as teenagers, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mehjabin Ismail Parkar, MD 6909 Brisbane Ct Ste 300, Sugar Land, TX 77479-7146 Ph: () - | Mehjabin Ismail Parkar, MD 6909 Brisbane Ct Ste 300, Sugar Land, TX 77479-4922 Ph: (281) 801-7855 |
News Archive
Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.
Children placed with a relative after being removed from their home for maltreatment have fewer behavioral and social skills problems than children in foster care, but may have a higher risk for substance use and pregnancy as teenagers, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
› Verified 4 days ago
Monica Kalra, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14023 Southwest Fwy, Sugar Land, TX 77478 Phone: 281-325-4100 | |
Dr. Brent Devin Reed, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15200 Southwest Fwy Ste 175, Sugar Land, TX 77478 Phone: 713-461-2915 Fax: 713-461-5307 | |
Robbyn Lucille Traylor, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2415 Town Center Dr, Ste 300, Sugar Land, TX 77478 Phone: 281-201-0657 | |
Dr. Cedela Abdulla, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3533 Town Center Blvd S, Ste. 200, Sugar Land, TX 77479 Phone: 713-772-0793 Fax: 281-781-2557 | |
Wyntria Lacabe-moore, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1403 Highway 6, Sugar Land, TX 77478 Phone: 832-260-0640 | |
Dr. Abraham K. Peringol, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 14815 Southwest Fwy, Sugar Land, TX 77478 Phone: 281-565-2140 Fax: 281-565-2174 | |
Owen Capocyan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4911 Sandhill Dr, Sugar Land, TX 77479 Phone: 816-334-9302 |